TY  - JOUR
A1  - Tschorn, Mira
A1  - Rieckmann, Nina
A1  - Arolt, Volker
A1  - Beer, Katja
A1  - Haverkamp, Wilhelm
A1  - Martus, Peter
A1  - Waltenberger, Johannes
A1  - Müller-Nordhorn, Jacqueline
A1  - Ströhle, Andreas
T1  - Erkennungsgüte dreier deutschsprachiger Screeninginstrumente für Depression bei hospitalisierten Patienten mit koronarer Herzerkrankung
T1  - Diagnostic Accuracy of German Depression Screenings in Patients with Coronary Heart Disease
JF  - Psychiatrische Praxis
N2  - Ziel Vergleich der Erkennungsgüte von drei Depressions-Screeninginstrumenten bei Patienten mit koronarer Herzerkrankung (KHK).
Methodik 1019 KHK-Patienten erhielten den Patient Health Questionnaire (PHQ-9 und PHQ-2) und die Hospital Anxiety and Depression Scale (HADS-D) sowie ein klinisches Interview (Composite International Diagnostic Interview) als Referenzstandard.
Ergebnisse Bezüglich der Erkennungsgüte waren PHQ-9 und HADS-D dem PHQ-2 überlegen. Optimale Cut-off-Werte waren 7 (PHQ-9 und HADS-D) und 2 (PHQ-2).
Schlussfolgerung PHQ-9 und HADS-D haben eine vergleichbare Diskriminationsfähigkeit für depressive Störungen bei KHK-Patienten.
N2  - Objective To compare the diagnostic accuracy of German depression screening instruments in patients with coronary heart disease (CHD). Methods 1019 CHD patients completed the Patient Health Questionnaire (PHQ-9 and PHQ-2) and the Hospital Anxiety and Depression Scale (HADS-D). The Composite International Diagnostic Interview served as reference standard for "any depressive disorder" and "major depression". Results The accuracy of the PHQ-9 and the HADS-D was comparable according to the area under the curve, and both were superior to the PHQ-2. The optimal cut-off according to the Youden index (maximum sum of sensitivity and specificity) was 7 for both instruments. At this optimal cut-off, the PHQ-9 had a higher sensitivity compared to the HADS-D, but a lower specificity (below 68). Results remained similar when patients who reported that they currently underwent treatment for depression were excluded. Conclusion The PHQ-9 and the HADS-D have comparable overall diagnostic accuracy in CHD patients. In line with previous screening studies with CHD patients, the optimal cut-offs were below the cut-offs that are recommended in the literature.
KW  - coronary artery disease
KW  - depression
KW  - diagnosis
KW  - screening
KW  - validity
Y1  - 2019
U6  - https://doi.org/10.1055/s-0042-123434
SN  - 0303-4259
SN  - 1439-0876
VL  - 46
IS  - 1
SP  - 41
EP  - 48
PB  - Thieme
CY  - Stuttgart
ER  - 
TY  - JOUR
A1  - Tschorn, Mira
A1  - Kuhlmann, Stella Linnea
A1  - Rieckmann, Nina
A1  - Beer, Katja
A1  - Grosse, Laura
A1  - Arolt, Volker
A1  - Waltenberger, Johannes
A1  - Haverkamp, Wilhelm
A1  - Müller-Nordhorn, Jacqueline
A1  - Hellweg, Rainer
A1  - Ströhle, Andreas
T1  - Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease
JF  - Acta Neuropsychiatrica
N2  - Objective: 
Depression and coronary heart disease (CHD) are highly comorbid conditions. Brain-derived neurotrophic factor (BDNF) plays an important role in cardiovascular processes. Depressed patients typically show decreased BDNF concentrations. We analysed the relationship between BDNF and depression in a sample of patients with CHD and additionally distinguished between cognitive-affective and somatic depression symptoms. We also investigated whether BDNF was associated with somatic comorbidity burden, acute coronary syndrome (ACS) or congestive heart failure (CHF). 

Methods: 
The following variables were assessed for 225 hospitalised patients with CHD: BDNF concentrations, depression [Patient Health Questionnaire-9 (PHQ-9)], somatic comorbidity (Charlson Comorbidity Index), CHF, ACS, platelet count, smoking status and antidepressant treatment. 

Results: 
Regression models revealed that BDNF was not associated with severity of depression. Although depressed patients (PHQ-9 score >7) had significantly lower BDNF concentrations compared to non-depressed patients (p = 0.04), this was not statistically significant after controlling for confounders (p = 0.15). Cognitive-affective symptoms and somatic comorbidity burden each closely missed a statistically significant association with BDNF concentrations (p = 0.08, p = 0.06, respectively). BDNF was reduced in patients with CHF (p = 0.02). There was no covariate-adjusted, significant association between BDNF and ACS. 

Conclusion: 
Serum BDNF concentrations are associated with cardiovascular dysfunction. Somatic comorbidities should be considered when investigating the relationship between depression and BDNF.
KW  - depression
KW  - BDNF
KW  - coronary heart disease
KW  - heart failure
KW  - somatic comorbidity
KW  - acute coronary syndrome
Y1  - 2020
U6  - https://doi.org/10.1017/neu.2020.31
SN  - 1601-5215
SN  - 0924-2708
VL  - 33
IS  - 1
SP  - 22
EP  - 30
PB  - Cambridge Univ. Press
CY  - Cambridge
ER  -